Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.61 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.43 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098563 | 0.89 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL30955021 | 0.83 | KEAP1 (0.44) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL30300276 | 0.83 | AKR1C2 (0.50) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL671102 | 0.83 | AKR1C2 (0.50) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL19971600 | 0.83 | KEAP1 (0.44) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL25340705 | 0.81 | AKR1C3 (0.53) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL16122465 | 0.81 | TTR (0.54) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL31457965 | 0.81 | AKR1C4 (0.44) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL18000505 | 0.81 | AKR1C4 (0.44) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL29509769 | 0.81 | AKR1C3 (0.53) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | BACE2, PSEN2, BACE1 | AKR1C3 4539/4885AKR1C2 4095/4885AKR1C1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.